Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Spondyloarthritis
Do you start methotrexate to prevent anti-drug antibody development when using TNF inhibitors for the treatment of axial spondyloarthritis?
Related Questions
How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?
In a patient with a Factor V Leiden heterozygous mutation but no prior thrombosis, would you consider using a JAK inhibitor for the treatment of spondyloarthritis or rheumatoid arthritis if other options have been ineffective?
In patients undergoing MRI evaluation for inflammatory back pain, how long do you recommend they hold NSAIDs prior to imaging?
How do you manage flares of axial spondyloarthritis in patients already on biologic therapy who were previously controlled?
How would you approach the management of HLA-B27-associated recurrent uveitis and inflammatory back pain with a recent history of melanoma?
How would you approach a patient with axial spondyloarthritis who develops new-onset proteinuria?
In a patient with active spondylarthritis and uveitis who cannot take TNF inhibitors, what is your next agent of choice?
Does the presence of facet joint effusions on lumbar spine MRI increase your suspicion for axial spondyloarthritis?
Which biologics are you comfortable combining with vedolizumab for spondyloarthritis or psoriatic arthritis patients in the setting of well-controlled inflammatory bowel disease?
Do you consider it safe to continue adalimumab for spondyloarthritis in a patient who develops localized melanoma if the adalimumab has worked well?
